Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
出版年份 2020 全文链接
标题
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
作者
关键词
-
出版物
EMBO Molecular Medicine
Volume -, Issue -, Pages -
出版商
EMBO
发表日期
2020-07-20
DOI
10.15252/emmm.201911416
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
- (2018) Gianni Bisogno et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
- (2018) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
- (2016) Y. Shaked et al. CANCER RESEARCH
- Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
- (2016) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
- (2016) Hyejin Cho et al. NATURE
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
- (2015) Lieke H J Simkens et al. LANCET
- Rationale for metronomic chemotherapy in phase III trials
- (2015) Robert S. Kerbel et al. Nature Reviews Clinical Oncology
- Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
- (2014) J. Dekervel et al. CLINICAL CANCER RESEARCH
- Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
- (2014) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overexpression of Hypoxia Inducible Factor-1 Alpha is an Independent Risk Factor for Recurrence After Curative Resection of Colorectal Liver Metastases
- (2013) Manabu Shimomura et al. ANNALS OF SURGICAL ONCOLOGY
- EMT is the dominant program in human colon cancer
- (2013) Andre Loboda et al. BMC Medical Genomics
- Tumor Cells Upregulate Normoxic HIF-1 in Response to Doxorubicin
- (2013) Y. Cao et al. CANCER RESEARCH
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis
- (2013) Raul Aguirre-Gamboa et al. PLoS One
- A Nontranscriptional Role for HIF-1 as a Direct Inhibitor of DNA Replication
- (2013) M. E. Hubbi et al. Science Signaling
- Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
- (2012) Christina Hackl et al. GUT
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
- (2012) L. Schito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Angiogenesis in Synchronous and Metachronous Colorectal Liver Metastases
- (2011) Gesiena E. van der Wal et al. ANNALS OF SURGERY
- Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
- (2011) David Venet et al. PLoS Computational Biology
- Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling
- (2010) S. Rey et al. CARDIOVASCULAR RESEARCH
- Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications
- (2009) Dan Cao et al. BMC CANCER
- Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
- (2009) K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started